Please assess the completion status of the following clinical trial:

Trial Title: Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of Crohn's disease localised in the ileum and/or colon, documented either radiologically or endoscopically at least 3 months previously;~* patients with a CDAI of ≥ 220 to ≤ 400;~* patients capable of and willing to conform to the study protocol;~* patients who have provided signed and dated written informed consent.~Exclusion Criteria:~* patients potentially needing immediate surgery for Crohn's disease, including patients with occlusive symptoms and/or stenotic tract with dilation above;~* patients with active perianal Crohn's disease;~* patients with other infectious, ischemic, or immunological diseases with gastrointestinal involvement;~* patients with symptoms attributed to Short Bowel Syndrome or previous surgery;~* patients with stoma;~* patients affected by upper gastro-intestinal disease (gastro-duodenum-jejunum Crohn's disease) alone or in combination with colitis or ileitis;~* patients treated with: oral steroids and budesonide less than 30 days prior to screening; i.v. steroids less than 30 days prior to screening; antibiotics (such as metronidazole, tinidazole, ciprofloxacin, clarithromycin) less than 15 days prior to screening;~* rectal steroids less than 30 days prior to the screening visit;~* anti-tumour necrosis factor (anti-TNF) and other biological therapies less than 6 months prior to the screening visit;~* pregnant women or nursing mothers;~* females of childbearing age (unless surgically sterile) without a negative urine pregnancy test at screening and at enrolment;~* patients with severe hepatic insufficiency (Child C);~* patients with severe cardiac insufficiency (NYHA - New York Heart Association classes 3 - 4);~* patients with known hypersensitivity to Rifaximin;~* any condition or circumstance that would prevent completion of the study or interfere with analysis of study results, including a history of drug or alcohol abuse, mental illness or non-compliance with treatments or visits, with immunological (including HIV infection), haematological or neoplastic disease;~* withdrawal of informed consent;~* patients who have used any investigational drug (except biological therapies) within 3 months prior to screening;~* patients who have donated 250 ml or more of blood in the last 3 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Rifaximin-EIR tablet 1x400 mg + Placebo 2 tablets bid
- B (Type: EXPERIMENTAL): Rifaximin-EIR tablet 2x400 mg + Placebo 1 tablet bid
- C (Type: EXPERIMENTAL): Rifaximin-EIR tablet 3x400 mg bid
- D (Type: PLACEBO_COMPARATOR): Placebo 3 tablets bid

Based on this trial design, predict the completion outcome and termination type (if applicable).